Last reviewed · How we verify

paclitaxel/anthracycline — Competitive Intelligence Brief

paclitaxel/anthracycline (paclitaxel/anthracycline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane and anthracycline. Area: Oncology.

phase 3 Taxane and anthracycline Oncology Small molecule Live · refreshed every 30 min

Target snapshot

paclitaxel/anthracycline (paclitaxel/anthracycline) — Tao OUYANG. Paclitaxel works by inhibiting cell division, while anthracyclines intercalate DNA strands to prevent cell replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
paclitaxel/anthracycline TARGET paclitaxel/anthracycline Tao OUYANG phase 3 Taxane and anthracycline

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane and anthracycline class)

  1. Tao OUYANG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paclitaxel/anthracycline — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-anthracycline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: